Advanced chondrosarcomas: role of chemotherapy and survival. - Wikidata - awgldk - TriplyDB

Advanced chondrosarcomas: role of chemotherapy and survival.

Advanced chondrosarcomas: role of chemotherapy and survival.

http://www.wikidata.org/entity/Q37265042

about

The Identification of Prognostic Factors and Survival Statistics of Conventional Central Chondrosarcoma Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.Treatment pathway of bone sarcoma in children, adolescents, and young adults Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013.3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.Response of conventional chondrosarcoma to gemcitabine alone: a case report Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years.Mesenchymal Chondrosarcoma in Children and Young Adults: A Single Institution Retrospective Review.No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone Dedifferentiated chondrosarcoma: Radiological features, prognostic factors and survival statistics in 23 patients GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study.Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study "Advances in the surgical management of bone tumors".Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells.Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.Chondrosarcoma of the Osseous Spine: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors Using the SEER Registry From 1973 to 2012.Multimodality Treatment of Skull Base Chondrosarcomas: The Role of Histology Specific Treatment Protocols.Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.TGF-β signalling and PEG10 are mutually exclusive and inhibitory in chondrosarcoma cells Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept.Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance.Outcome of advanced, unresectable conventional central chondrosarcoma.BAG3 promotes chondrosarcoma progression by upregulating the expression of β-catenin.[Osteosarcomatous dedifferentiated chondrosarcoma].High-grade chondrosarcoma of the larynx: a case report and literature review Sorafenib in patients with progressed and refractory bone tumors

P2860

Q26774943-B4D34978-09E2-4454-ADCA-B29C2F7815B0 Q33276109-22A8D647-A4BC-468D-9438-1679BCCCC3FA Q33835657-3043352C-B57D-476D-B9EE-2C83C2287D98 Q34038664-CC773F1E-F5ED-4F32-B74B-039720AFFF3B Q35172602-E2538B2B-9716-4102-B94A-D7DAD62DB06B Q35194125-2D6199B1-2FF9-4A52-BBAE-75B5AB73FB47 Q35302545-59C4A321-B5B0-4ACE-B0A8-A3F019D2BA0D Q35749494-2FC44AF6-132D-4D30-B1CC-5A473109FAA0 Q36078319-F1119D29-8DC3-485E-8E64-1DBB28A75FF2 Q36310646-DD2F4781-5C7E-4F18-BFBF-D2D6EEC0DB59 Q37265046-755070EA-E5BF-4A4D-B045-ED0A98F7CE4F Q37427998-961BA36B-1D12-421B-9E05-870FC736F451 Q38213900-1843E739-4FA6-46D9-9B68-576B2253B4A9 Q38602635-DE8DE56F-9C62-40BD-9729-06C686B44363 Q38721488-2D3A44B2-54A0-48CB-BD9C-19C138B48E1D Q38811197-64B41067-48DF-4EC7-8D9E-CAFE0FE6837F Q38820580-D356D189-4FA7-47B1-B1EE-78719E69A92C Q38860922-82A3DC7C-DB1A-406C-A5CF-4CA2CFBD8508 Q41007674-A7FF384A-F484-4762-9D3A-10EDF9153AF1 Q42677448-6844F04D-C953-4521-A77E-C61BBA03714A Q46265366-DB02B576-B6AB-4FC4-A754-B7B0AEAC027C Q47121012-7E556315-A249-4B5D-86EC-03BE6D078171 Q48182725-DC37447C-BE91-42F1-A70A-D2CFC32670B0 Q50660686-D5741AA5-1802-4A61-A41C-0FF91791BB45 Q52684027-C8F10670-253E-4214-BD8A-9758C5D88E9F Q52864036-4BD35C17-7BAC-44EA-AAE9-4398B9007523 Q58765605-60110115-476A-4BC4-BC3D-7A74795E4A91 Q58774317-EAE156DE-973B-40C5-8538-D0CE111D8F30

P2860

Advanced chondrosarcomas: role of chemotherapy and survival.

http://www.wikidata.org/entity/Q37265042

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Advanced chondrosarcomas: role of chemotherapy and survival.

@en

Advanced chondrosarcomas: role of chemotherapy and survival.

@nl

type

label

Advanced chondrosarcomas: role of chemotherapy and survival.

@en

Advanced chondrosarcomas: role of chemotherapy and survival.

@nl

prefLabel

Advanced chondrosarcomas: role of chemotherapy and survival.

@en

Advanced chondrosarcomas: role of chemotherapy and survival.

@nl

P1433

Q37265042-A4ABA711-49E7-4FE5-9832-CA7EAE6C45D7

P1476

Q37265042-A1DF2872-BC2A-49AF-801E-53E50F941144

P2093

Q37265042-3417EE9C-3B8F-4B03-9504-C9E6CE85F307

Q37265042-4AC39A6F-B629-439B-907F-11D7F9183BE9

Q37265042-63734792-53F5-41AC-8C29-DBE156972E10

Q37265042-850172FD-904B-4A9C-AF75-2F4FA003962B

Q37265042-A728AE24-CE60-4F9F-AA50-87E27F5FEAC9

Q37265042-AC965F7B-B037-4E00-84EA-8F0D318A8D48

Q37265042-B17C0122-BB70-451F-A1D4-0591E8C6A2DD

Q37265042-E14FEDAF-6B99-4BEA-8BF6-B59BA0D5030F

Q37265042-E51B4578-3175-4E5E-9C73-2F3C8CD30D5D

Q37265042-E6ECF911-7CE2-4D08-9A2D-DE1C4E2E6068

P2860

Q37265042-0636C192-69B1-4272-87BB-DA069053C216

Q37265042-0C30713E-ECDF-4D7F-8CCE-E5DAFFE14235

Q37265042-108B0EF7-8124-4A86-BE64-C4BEC27C0EC7

Q37265042-20460A1C-DF3A-4712-ACAC-259E29B6B9CE

Q37265042-324C728D-2B4E-4472-94FD-90FF5A33AA77

Q37265042-4971039D-5D4C-4125-B4B4-DCC672EC8732

Q37265042-666E32F4-7672-46F0-903C-42682BF0DBE0

Q37265042-78F2DD9A-E09E-4E48-A2CE-800A66A1006C

Q37265042-831ED23D-E384-4AB9-BD71-FD447DACD626

Q37265042-902FE248-0A36-44C1-96F0-977FAB0D74DA

P304

Q37265042-8D5F6D49-A957-4855-943C-8ADC068D9B47

P31

Q37265042-9CC3BD49-B4C6-4D46-AFA2-63BC51B922D9

P356

Q37265042-A9A39BEA-20A2-43E2-A85E-81B251CC6356

P433

Q37265042-56360226-6170-49CC-8DAA-8C86FC50F216

P478

Q37265042-A15BC72B-A0C8-4FFF-9F50-A4461A7D73AE

P50

Q37265042-02A484F0-D0FF-408A-883B-F74A76AC825F

Q37265042-591BD11E-0CEF-43F4-9E94-388ECB5CA3D0

Q37265042-82BF5965-A696-4C5E-B57F-E1C60CEA19A4

Q37265042-89384D9C-EF2C-4C7D-AA58-B7432575463F

Q37265042-A5170445-4B25-4E88-B190-5C5A7BB70681

Q37265042-C928BE45-7DEE-487F-8DF7-50E98D8C6AD3

Q37265042-E09125AD-FCF7-40CC-B676-AE0C3416E276

P577

Q37265042-DD3031D9-73B6-4C4B-8877-E38A8957970F

P5875

Q37265042-D3A0279F-BF50-40FE-8882-430CE342567E

P698

Q37265042-8C6BF69D-2E6A-466E-8E53-10E7161EF5DA

P921

Q37265042-5CA2EE69-A074-43BD-B025-2F4F6BBF2B7D

Q37265042-88B2ED6A-CF3C-4045-8954-D14DC4C8D1C8

P932

Q37265042-05E978E2-B032-4CAC-AB22-0EF1905ABADC

P356

P1433

Annals of Oncology

P1476

Advanced chondrosarcomas: role of chemotherapy and survival

@en

P2093

A Italiano

http://www.w3.org/2001/XMLSchema#string

A Le Cesne

http://www.w3.org/2001/XMLSchema#string

C Perrin

http://www.w3.org/2001/XMLSchema#string

E Bompas

http://www.w3.org/2001/XMLSchema#string

F Bertucci

http://www.w3.org/2001/XMLSchema#string

F Duffaud

http://www.w3.org/2001/XMLSchema#string

I Ray Coquard

http://www.w3.org/2001/XMLSchema#string

J E Kurtz

http://www.w3.org/2001/XMLSchema#string

L Chaigneau

http://www.w3.org/2001/XMLSchema#string

O Collard

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data.

Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.

Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation

Chondrosarcoma and peroxisome proliferator-activated receptor.

GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study.

P304

2916-2922

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDT374

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Emanuela Palmerini

P577

2013-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257529649

http://www.w3.org/2001/XMLSchema#string

P698

24099780

http://www.w3.org/2001/XMLSchema#string

P921

P932

3811906

http://www.w3.org/2001/XMLSchema#string